Strijbos E, et al. - In this study, researchers assessed 47 patients to analyze the effectiveness and safety of influenza vaccination in those who have myasthenia gravis with acetylcholine receptor antibodies (AChR MG). They recorded achievement of seroprotective titer (HI ≥ 1:40) in 89.4% of MG patients vs 93.6% in healthy controls for the H3N2 strain, 95.7% vs 97.9% for the H1N1 strain, and 46.8 vs 51% for the B-strain in post-vaccination individuals. They observed no alteration in the titers of disease-specific AChR antibodies, even 4 weeks following vaccination. In response to an influenza vaccination, they noticed no aggravation of MG symptoms as per the clinical outcome scores, nor any difference in antibody response between patients with AChR MG and healthy controls.